Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
WSJ PRICE TARGET CYDY $4.00
"leronlimab | The Rio Times" https://riotimesonline.com/brazil-news/tag/leronlimab/
except for the secondary endpoint in the critically ill subpopulation
Another scenario is the Brazil trials DO pan out AND the HIV BLA is back on track within a few months. This scenario is far more likely.
200,000 vials set aside for the Philippines... and now there is a purchase order with the Philippines... do the math $240 million
Proof of substantial revenue will be required to move the needle from here out.
CytoDyn is a revenue producing company. Read the PR again
So your way of being objective is to plug your ears close your eyes and say this isn't happening?
When trial started in Brazil PR hits expect CYDY to move towards $3
Please provide the details on CYDY after the Memorial Day weekend
Purchase Order
"a fairly substantial portion improved"
Dr Yang speaking of the patients he treated with Leronlimab. This is consistent with every doctor that has treated patients with Leronlimab.
leronlimab is the best Covid treatment
HGEN again closed lower. There is no capitulation, shorts will continue to attack this damaged company until it enters bankruptcy and shutters.
*FDA scrutinizes HGEN's study and forces an extended study.
*CEO Durrant sold the same preferred shares twice, defrauding retail investors to favor Wall Street Insiders.
*Tainted studies. Most recent study involved patients on other drugs removing the ability of HGEN to say their drug was responsible for recovery.
*5 out of 12 actually recovered on HGEN's drug alone. 50% versus the control arm which had an astounding 81% recovery.
*HGEN's drug was based off of stolen IP from a Chagas treatment they abandoned. If they lose in court they will owe damages and royalties.
*HGEN changed end points and never released efficacy results.
*Massive Reverse Split, 5 to 1 unsupported by any science, EUAs, or critically reviewed studies proving it passes academic muster.
*Mayo Clinic describes Control Arm only study, Mayo did not do the gold standard double blind placebo study.
*HGEN's springboard study took 11 patients and classified them as COVID severe cases. None of them were on vents and described with moderate symptoms.
*NASDAQ uplisting requires minimums that HGEN doesn't meet.
*NASDAQ monitors volatility as apart of uplisting. HGEN has had a dramatic fall. Reverse Split results will be heavily scrutinized.
*Reverse Split taking place on OTC market. Small equity holders set to lose initial positions. Retail investors will be spooked.
*Most institutions require a minimum 5 dollar share price and a security to be listed on an exchange to offer it or pick it up as an investment. HGEN's desperation play requires the "cavalry to come over the hill" to remain viable.
HGEN is a scam run, short, but don't buy or hold this junk!
All of this is irrelevant from an investment standpoint with CYDY. The number of covid-19 cases won't stop approval for Leronlimab. After Leronlimab receives first approval it will stabilize CytoDyn as a pharma company and start revenue. COVID-19 will be here indefinitely and approval for Leronlimab will open the door for other ARDS.
That's the exact short talking point in May of 2020, COVID-19 is still here and changing, it's now killing younger healthy people.
LL is very effective for Covid, the trial in Brazil with 4 doses for critical patients will show that. Smart move for CytoDyn to continue CD12 in Brazil where it can be filled quickly.
Macleods Pharmaceuticals...Academic Research Organization (ARO) - Albert Einstein Israelite Hospital (AEIH) in São Paulo, Brazil ....multiple hospitals in Philippines stocking Leronlimab
works in hospitals
The FDA scientist were informed 4 doses of Leronlimab will save lives. Apparently they made the decision they don't care.
Don't be scared don, it's going to save alot of lives when they sell Leronlimab in India, you should be excited about it!
So you're conclusion is Macleods will be selling Leronlimab in multiple different countries not just India and Brazil. Good to know
"Other news to note for May 13, 2021 | 2021-05-13 | BioWorld" https://www.bioworld.com/articles/507066-other-news-to-note-for-may-13-2021
If you're going to post a fake doctored search screen at least get his race correct. Nader's a white guy??
I heard NP was spotted changing lanes..WITHOUT USING HIS SIGNAL!!
That part of the interview really got my attention, also caught the attention of Cito Beltran and when he pressed NP for more info on India NP responded they are a public company and must make an official announcement. We may see major news come from India before Philippines.
Why did HGEN dump after they released that preprint? Is HGEN a scam and the market detected this after seeing the data?
So you're saying there will be a buyout this week?!! Trading will be halted for the buyout? Or CYDY PR's news of EUA in India this week and trading is halted as it's gapping up to $50? My bet would be on the EUA, when asked about India NP said they were in talks with them but when pressed on the subject he couldn't answer because CytoDyn is a public company and they would need to PR an announcement.
Here's a short version of the interview today
He can't discuss India right now because they are a public company and must make an announcement. This could be huge!
HGEN again closed lower. There is no capitulation, shorts will continue to attack this damaged company until it enters bankruptcy and shutters.
*FDA scrutinizes HGEN's study and forces an extended study.
*CEO Durrant sold the same preferred shares twice, defrauding retail investors to favor Wall Street Insiders.
*Tainted studies. Most recent study involved patients on other drugs removing the ability of HGEN to say their drug was responsible for recovery.
*5 out of 12 actually recovered on HGEN's drug alone. 50% versus the control arm which had an astounding 81% recovery.
*HGEN's drug was based off of stolen IP from a Chagas treatment they abandoned. If they lose in court they will owe damages and royalties.
*HGEN changed end points and never released efficacy results.
*Massive Reverse Split, 5 to 1 unsupported by any science, EUAs, or critically reviewed studies proving it passes academic muster.
*Mayo Clinic describes Control Arm only study, Mayo did not do the gold standard double blind placebo study.
*HGEN's springboard study took 11 patients and classified them as COVID severe cases. None of them were on vents and described with moderate symptoms.
*NASDAQ uplisting requires minimums that HGEN doesn't meet.
*NASDAQ monitors volatility as apart of uplisting. HGEN has had a dramatic fall. Reverse Split results will be heavily scrutinized.
*Reverse Split taking place on OTC market. Small equity holders set to lose initial positions. Retail investors will be spooked.
*Most institutions require a minimum 5 dollar share price and a security to be listed on an exchange to offer it or pick it up as an investment. HGEN's desperation play requires the "cavalry to come over the hill" to remain viable.
HGEN is a scam run, short, but don't buy or hold this junk!
It was brought, the market sniffed it and took a dump on HGEN. Get over it and find less scam driven OTC stock.
Why is this stock struggling to break $20? Why are there no buyers? Could this be part of the reason?
. A Reasonable Perspective For New Investors.
Consider the following:
You have a stock backed by multiple investment groups not related to biotech. You have a CEO still under active investigation for securities fraud, and the company still facing an IP theft lawsuit. The recent announcement of the drug being safe and nothing more is being touted as efficacy results. Then remember after the last study no efficacy results have been offered for public analysis.
After all those thoughts, consider this:
For financial giants JP Morgan and other titans of the industry a measly 8 million shares has become a herculean task to sell.
The question is why can't these major market makers complete this kind of offering in a week?
The answer is right there.
No one wants to buy.
Why?
Well what is HGEN then just a few names, some smartly dressed PR, and the legacy of Martin Shrekli?
So there you go. HGEN. Some old scam, same old bad science, just a new sense of urgency.
The recovery numbers look impressive now that people are being treated with Leronlimab! This is great news!!!